抗人A血型杂交瘤细胞高密度培养条件的研究

抗人 A 血型杂交瘤15B_4细胞在 CelliGen 细胞培养罐中进行连续灌注培养,细胞密度达1.6×10~7/ml。每天灌注新培养液量由1000ml 增到2300ml,第14天后又逐日减少至1000ml,死细胞数随着转速的增加和灌注量的减少而增多。血凝效价呈梯度上升,滴度达到2~(14),相当于腹水效价。培养6天 IgM 产量为0.2克/升/天,10～18天波动在1.45～1.8克/升/天。15B_4细胞代谢与葡萄糖、乳酸有关,与氨无关。CelliGen 自控效果较好,适用于杂交瘤细胞的高密度培养。搅拌速度在120～150r/min 对细胞产生的剪切力有明显地破坏作用。溶氧控制系统有待改进。     

4 beta, 15-Diacetoxyscirpenol induces cytotoxicity and alterations in phagocytic and Fc-receptor expression functions in chicken macrophages in vitro

Teleoperation is frequently performed with misalignments between operator or camera viewing direction and controller orientation. Examples of this occur in endoscopic surgery and in teleoperation with multiple camera views. The objective of this study was to find a method to automatically compensate for those misalignments so that human operators performing tasks under such scenarios could achieve levels of performance comparable to aligned conditions without additional training requirements. In this paper we report on a set of experiments conducted to test a method developed for that purpose. Participants were asked to track a randomly moving target on a computer display using a cursor controlled with a joystick. Performance was recorded under various visual-motor misalignments with and without automated compensation. Results indicated significant improvements in operator performance through use of automatic compensation only under certain types of misalignment. Actual or potential applications of this research include teleoperation and endoscopic surgery.     

UHMWPE混炼接枝马来酸酐研究

讨论了超高相对分子质量聚乙烯(UHMWPE)混炼接枝马来酸酐(MAH)过程中，单体MAH用量、引发剂DCP用量、交联抑制剂己内酰胺(CAILA)用量、流动改性剂硬脂酸钙(CaSt2)用量及混炼温度、时间等工艺条件对UHMWPE接枝率和凝胶含量的影响。用红外光谱表征了接枝物的存在。并用滴定分析法和重量分析法测定了接枝物UHMWPE～g～MAH的接枝率和凝胶含量。实验表明，MAH用量为5份、DCP为0．15份、CALA为0．1份、CaSt2为1份时。混炼温度175∽180℃。混炼时间14min时，可得到接枝率0．75％、凝胶含量1．48%的UHMWPE接枝物。     

强化单螺杆挤出机内层流混合的方法

综述了单螺杆挤出机内聚合物熔体层流混合机理的研究进展，对提高混合的措施进行了分析总结，指出了进一步强化混合效果的方法。     

Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis

BACKGROUND: Chronic myelogenous leukemia (CML) is an indolent but ultimately fatal disease. Because the natural history of CML varies and quality of life with CML may be excellent until shortly before death, deciding whether and when to pursue unrelated donor bone marrow transplantation is often difficult. OBJECTIVE: To compare early transplantation, delayed transplantation, and no transplantation for patients with chronic-phase CML on the basis of discounted, quality-adjusted life expectancy. DESIGN: A markov model comparing different strategies was constructed. This model considers patient age, quality of life, risk aversion, and the competing risks for CML progression and transplant toxicity. SETTING: Therapeutic decision at the time of diagnosis of CML. PATIENTS: The base case is a 35-year-old patient with intermediate-prognosis CML. Younger and older patients with better and worse prognoses are also evaluated. INTERVENTION: Early transplantation, delayed transplantation, and no transplantation. MEASUREMENTS: Quality-adjusted, discounted life expectancy. RESULTS: For patients with newly diagnosed CML, transplantation within the first year provides the greatest quality-adjusted expected survival, although this benefit decreases with increasing patient age. For a 35-year-old patient with intermediate-prognosis CML, transplantation within the first year results in 53 more discounted, quality-adjusted years of life expectancy than does no transplantation. This finding is robust even with varying baseline assumptions. CONCLUSIONS: These results support the use of early unrelated donor bone marrow transplantation for most patients with CML.